更新于：2024-11-01

ω-3-Fish Oil Medium and Long Chain Fat Emulsion

ω-3 鱼油中/长链脂肪乳

更新于：2024-11-01

概要

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

B. Braun Melsungen AG

在研机构

B. Braun Melsungen AG

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2014-12-23)

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

100 项与 ω-3 鱼油中/长链脂肪乳相关的临床结果

登录后查看更多信息

100 项与 ω-3 鱼油中/长链脂肪乳相关的转化医学

登录后查看更多信息

100 项与 ω-3 鱼油中/长链脂肪乳相关的专利（医药）

登录后查看更多信息

项与 ω-3 鱼油中/长链脂肪乳相关的文献（医药）

2024-10-01·JAMA Dermatology

A Secondary Analysis of a Randomized Clinical Trial

Article

作者: Kolmert, Johan ; Chen, Liang ; Vahman, Nilo ; Schoos, Ann-Marie M. ; Lasky-Su, Jessica A. ; Brustad, Nicklas ; Rasmussen, Morten A. ; Stokholm, Jakob ; Ali, Mina ; Chawes, Bo ; Bønnelykke, Klaus ; Wheelock, Craig E. ; Wang, Tingting ; Lovrić, Mario ; Luo, Yang ; Ebrahimi, Parvaneh

ImportanceEicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway.ObjectiveTo explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype.Design, Setting, and ParticipantsThis prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023.InterventionA total of 736 pregnant women at 24 weeks’ gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum.Main Outcomes and MeasuresRisk of childhood AD until age 10 years overall and by maternal COX1 genotype.ResultsAt age 10 years, 635 children (91%; 363 [57%] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (β, –0.46; 95% CI, –0.80 to –0.13; P = .006), which was also associated with COX1 rs1330344 genotype (β per C allele, 0.47; 95% CI, 0.20-0.73; P = .001). Although neither n-3 LCPUFA supplementation (hazard ratio [HR], 1.00; 95% CI, 0.76-1.33; P = .97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; P = .60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (P &lt; .001 for interaction). Among mothers with the TT genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs [61%]; HR, 0.70; 95% CI, 0.50-0.98; P = .04); there was no association for mothers with the CT genotype (209 [33%]; HR, 1.29; 95% CI, 0.79-2.10; P = .31), and risk was increased among offspring of mothers with the CC genotype (37 [6%]; HR, 5.77; 95% CI, 1.63-20.47; P = .007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (P = .002 for interaction).Conclusions and RelevanceIn this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the TT genotype.Trial RegistrationClinicalTrials.gov: NCT00798226

2024-10-01·Current Developments in Nutrition

Nutritional Optimization for Brain Health in Contact Sports: A Systematic Review and Meta-Analysis on Long-Chain ω-3 Fatty Acids and Neurofilament Light

Article

作者: Anthony, Ryan ; Sergi, Tina E ; Heileson, Jeffery L. ; Watson, Nora L. ; Macartney, Michael J ; Jagim, Andrew R. ; Macartney, Michael J. ; Peoples, Gregory E. ; Jagim, Andrew R ; Sergi, Tina E. ; Peoples, Gregory E ; Heileson, Jeffery L ; Watson, Nora L

BackgroundAccumulating evidence has highlighted the acute and chronic impact of repetitive subconcussive head impacts (rSHIs) in contact sports. Neurofilament-light (Nf-L), a brain-derived biomarker of neuroaxonal injury, elevates in concert with rSHI. Recently, long-chain ω-3 polyunsaturated fatty acids (LC ω-3 PUFAs) supplementation has been suggested to mitigate brain injury from rSHI as reflected by attenuation of Nf-L concentrations within contact sport athletes.ObjectiveUsing a systematic review with a meta-analysis, we aimed to determine the effect of LC ω-3 PUFA supplementation on Nf-L concentrations in athletes routinely exposed to rSHI.MethodsElectronic databases (PubMed and CINAHL) were searched from inception through January 2024. One-stage meta-analysis of individual participant-level data was used to detect changes in Nf-L concentrations between LC ω-3 PUFA and control/placebo (PL) groups from baseline to midseason (MS) and postseason (PS). Least square means (±SE) for Nf-L change from baseline were compared by treatment group for MS/PS using contrast t tests. Significance was set a priori at adjusted P ≤ 0.05.ResultsOf 460 records identified, 3 studies in collegiate American football players (n = 179; LC ω-3 PUFA = 105, PL = 71) were included in the meta-analysis. Compared with PL, the change in Nf-L concentrations was statistically similar at MS [mean difference (MD) = -1.66 ± 0.82 pg·mL-1, adjusted P = 0.09] and significantly lower at PS (MD = -2.23 ± 0.83 pg·mL-1, adjusted P = 0.02) in athletes following LC ω-3 PUFA supplementation.ConclusionsOur findings demonstrate preliminary support for the prophylactic administration of LC ω-3 PUFA in contact sport athletes exposed to rSHI; however, further research is required to determine the effective dosage required.This trial was registered at OSF (DOI: https://doi-org.libproxy1.nus.edu.sg/10.17605/OSF.IO/EY5QW).

2024-01-01·Advances in Nutrition

Corrigendum to “The Potential Cardiometabolic Effects of Long-Chain ω-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies” [Adv Nutr 14(4) (2023) 612–628]

作者: Lim, Hyunjung ; Bae, Jae Hyun ; Lim, Soo

100 项与 ω-3 鱼油中/长链脂肪乳相关的药物交易

登录后查看更多信息